Back to top

Astellas Pharma: Hold Rating Amid Growth Challenges and Product Limitations

Astellas Pharma, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Miki Sogi from Bernstein downgraded the ratin...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Astellas Pharma Inc. (ALPMY)